Oryx Bio-Tech to invest $300m in Summit Technopolis to set up country’s first bio-tech industry

Oryx Bio-Tech

Oryx Biotech, a subsidiary of Oryx Biotech Holdings based in China, inked a tripartite agreement with Summit Technopolis and BHTPA for a biotech investment worth $300 million.

 Oryx will set up their Plasma Fractionation Plant in Block II of Summit Technopolis to produce plasma derivatives also known as Life Saving Therapeutics and other related products - making it the first biotech investment in Bangladesh, said a press release. 

With a great need for plasma in the potential treatment of COVID-19, this is a timely investment for Bangladesh’s healthcare research and service sectors. It is expected that about 2,000 high-value science graduates will be employed to produce therapeutics such as Albumin, Immunoglobulin, and Coagulation factor VIII.

Muhammed Aziz Khan, founder chairman of Summit, said, “We are pleased to activate the nation's first and largest biotech investment of about $300 million on 25 acres of land and building provided by Summit Technopolis. 

It is most gratifying that this milestone plasma fractionation project which will open new horizons in Bangladesh’s development is happening in this auspicious year of Bangabandhu’s birth centenary.”

Hosne Ara Begum, MD of BHTPA, Abu Reza Khan, MD of Summit Technopolis, and David Bo, MD of Oryx Biotech, signed the tripartite agreement. Nasrul Hamid, state minister, Ministry of Power, Energy and Mineral Resources (MPEMR), and Zunaid Ahmed Palak, state minister for ICT, were present on the occasion at BCC Auditorium in the capital on Tuesday. 

The ceremony was virtually attended by Vice-Chairmen of Summit Group Muhammed Aziz, KhanJafer Ummeed Khan, Latif Khan, Farid Khan, Directors of Summit Group Ayesha Aziz Khan,  Azeeza Aziz Khan, Fadiah Khan, Salman Khan along with other senior officials and David Bo and his colleagues from China.

HM

Oryx Bio-Tech to invest $300m in Summit Technopolis to set up countrys first bio-tech industry

Oryx Bio-Tech

Oryx Biotech, a subsidiary of Oryx Biotech Holdings based in China, inked a tripartite agreement with Summit Technopolis and BHTPA for a biotech investment worth $300 million. Oryx will set up their Plasma Fractionation Plant in Block II of Summit Technopolis to produce plasma derivatives also known as Life Saving Therapeutics and other related products - making it the first biotech investment in Bangladesh, said a press release. With a great need for plasma in the potential treatment of COVID-19, this is a timely investment for Bangladeshs healthcare research and service sectors. It is expected that about 2,000 high-value science graduates will be employed to produce therapeutics such as Albumin, Immunoglobulin, and Coagulation factor VIII. Muhammed Aziz Khan, founder chairman of Summit, said, We are pleased to activate the nations first and largest biotech investment of about $300 million on 25 acres of land and building provided by Summit Technopolis. It is most gratifying that this milestone plasma fractionation project which will open new horizons in Bangladeshs development is happening in this auspicious year of Bangabandhus birth centenary. Hosne Ara Begum, MD of BHTPA, Abu Reza Khan, MD of Summit Technopolis, and David Bo, MD of Oryx Biotech, signed the tripartite agreement. Nasrul Hamid, state minister, Ministry of Power, Energy and Mineral Resources (MPEMR), and Zunaid Ahmed Palak, state minister for ICT, were present on the occasion at BCC Auditorium in the capital on Tuesday. The ceremony was virtually attended by Vice-Chairmen of Summit Group Muhammed Aziz, KhanJafer Ummeed Khan, Latif Khan, Farid Khan, Directors of Summit Group Ayesha Aziz Khan, Azeeza Aziz Khan, Fadiah Khan, Salman Khan along with other senior officials and David Bo and his colleagues from China. HM